Αποτελέσματα Αναζήτησης
25 Αυγ 2016 · The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in ...
The majority of universities that offer medical studies in Germany are public. Some of the great upsides of that are that they have comprehensive infrastructures and research networks in Germany, that they are free of charge (no tuition fees), and offer the opportunity to engage in doctoral studies as well.
1 Ιουν 2018 · Background: In INO-VATE, patients (pts) treated with InO vs standard chemotherapy (SC) had significantly greater remission rates and longer overall survival (OS), with 23% reduced risk of death (Kantarjian et al, NEJM 2016). Here we report detailed safety outcomes from long-term follow-up.
15 Απρ 2018 · Background: Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial. This subset analysis compared the efficacy and safety of InO in younger and older patients.
Abstract. Background: Inhaled nitric oxide (iNO) has been used for treatment of acute respiratory failure and pulmonary hypertension since 1991 in adult patients in the perioperative setting and in critical care.
No matter whether you want to come for a part of your studies, an elective or as a medical practicioner in Germany, but also if you want to come to Frankfurt as a degree student, here you will find first answers to your questions.
15 Μαρ 2021 · Methods: The efficacy of inotuzumab ozogamicin (InO), a humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin, was evaluated in R/R ALL patients in the phase 1/2 study 1010 (NCT01363297) and open-label, randomized, phase 3 study 1022 (INO-VATE; NCT01564784).
